Small private biotechs raise money in mostly early-stage financing
A trio of biotechs is looking to raise funds, to either kick operations off or to build up resources.
Moat Biotechnology, a biotech out of Oklahoma City focusing on intranasal or inhaled adenovirus vaccines, announced Tuesday that it raised $6.5 million in its first close — after launching the company and kicking off an initial funding round back in September.
Its co-founders — Scott Rollins and Russell Rother — are former Alexion executives, according to their LinkedIn profiles. Rollins, listed as one of Alexion’s co-founders and former head of drug development, left the company in 2008. Rother, Alexion’s former science chief, left in 2010.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.